Lambersart, France

Céline Monnet-Mars


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Céline Monnet-Mars: Pioneering Immunotherapy Innovations**

Introduction

Céline Monnet-Mars is a notable inventor based in Lambersart, France, recognized for his contributions to the field of immunotherapy. His innovative work focuses on the therapeutic applications of modified antibody Fc fragments, which play a critical role in treating autoimmune and inflammatory diseases.

Latest Patents

Monnet-Mars holds a patent for the invention titled "Use of modified Fc fragments in immunotherapy." This patent specifically relates to the use of antibody Fc fragments isolated as recombinant Fc fragments, which feature a modified affinity for at least one of the Fc receptors (FcR). His innovation is particularly noteworthy for its increased affinity to FcRn, potentially enhancing therapeutic outcomes in immunotherapy.

Career Highlights

Céline Monnet-Mars is currently associated with Laboratoire Français Du Fractionnement Et Des Biotechnologies, where he continues to advance research in biotechnology. His single patent underscores his commitment to pushing the boundaries of science in the health sector. The modifications he has developed in Fc fragments may significantly influence the future of treatment protocols for various autoimmune and inflammatory conditions.

Collaborations

In his professional journey, Monnet-Mars collaborates closely with colleagues such as Philippe Mondon and Alexandre Fontayne. Their collective expertise and insights contribute to the innovative environment at their laboratory, fostering the development of groundbreaking strategies in immunotherapy.

Conclusion

Céline Monnet-Mars exemplifies the spirit of innovation in the realm of biotechnology. His research into modified Fc fragments opens new avenues for effective therapies against autoimmune and inflammatory diseases. As he continues his work at Laboratoire Français Du Fractionnement Et Des Biotechnologies, the potential impact of his inventions on patient care remains promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…